Using bacteriocins to treat infections caused by Pseudomonas aeruginosa
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections
This study is looking at a new treatment called R-pyocins that could help fight tough infections caused by antibiotic-resistant bacteria, specifically Pseudomonas aeruginosa, and it aims to see how well this treatment works in the lab for people who have serious infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10877913 on NIH RePORTER |
What this research studies
This research investigates the use of R-pyocins, a type of bacteriocin, as a new treatment for infections caused by the antibiotic-resistant bacteria Pseudomonas aeruginosa. The approach focuses on the ability of R-pyocins to specifically target and kill P. aeruginosa without the risks associated with phage therapy, such as genetic transfer. The study will involve testing the effectiveness of R-pyocins in laboratory models to determine their potential as a therapeutic option for patients with severe infections. If successful, this could provide a novel way to combat infections that are difficult to treat with existing antibiotics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with acute or chronic infections caused by Pseudomonas aeruginosa, especially those with compromised immune systems or conditions like cystic fibrosis.
Not a fit: Patients with infections caused by bacteria other than Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from severe Pseudomonas aeruginosa infections, particularly those who are resistant to current antibiotics.
How similar studies have performed: While phage therapy has shown promise in treating bacterial infections, the use of R-pyocins is a relatively novel approach that has not been extensively validated in clinical settings.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Goldberg, Joanna B — Emory University
- Study coordinator: Goldberg, Joanna B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.